Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors - Trial NCT06242691
Access comprehensive clinical trial information for NCT06242691 through Pure Global AI's free database. This Phase 2 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 304 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 2
Mar 26, 2024
Mar 03, 2027
Primary Outcome
Number of Participants who Experience One or More Dose-Limiting Toxicities (DLTs),Number of Participants who Experience One or More Adverse Events (AEs),Number of Participants who Discontinue Study Intervention Due to an AE
Summary
The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in
 participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer,
 esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have
 received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of
 the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2
 will evaluate safety and efficacy of MK-1200 at 2 different doses
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06242691
Non-Device Trial